Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.

Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

It's the question on everyone's minds: What will it take for us to come out of this period of extreme social distancing and return to some semblance of normal life?

It turns out that the Centers for Disease Control and Prevention has been working on a plan to allow the U.S. to safely begin to scale back those policies. CDC Director Robert Redfield spoke with NPR on Thursday, saying that the plan relies on not only ramped-up testing but "very aggressive" contact tracing of those who do test positive for the coronavirus, and a major scale-up of personnel to do the necessary work.

The federal government Saturday unveiled the first detailed national system for tracking the coronavirus pandemic in the United States.

The new COVIDView system will provide weekly updates aimed at monitoring the outbreak across the country, based on the results of tests for the virus, people seeking care for flu-like systems and pneumonia and those diagnosed with COVID-19, the disease caused by the virus.

One of the nation's most important medical testing companies has acknowledged that it has a backlog of at least 115,000 coronavirus tests, which helps explain why so many desperate doctors and patients haven't been able to get tested.

Quest Diagnostics of Secaucus, N.J., says the backlog occurred because a company lab in San Juan Capistrano, Calif., where the company's coronavirus testing started, got overwhelmed when testing started to ramp up.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

STEVE INSKEEP, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

For the first time, scientists have used the gene-editing technique CRISPR to try to edit a gene while the DNA is still inside a person's body.

The groundbreaking procedure involved injecting the microscopic gene-editing tool into the eye of a patient blinded by a rare genetic disorder, in hopes of enabling the volunteer to see. They hope to know within weeks whether the approach is working and, if so, to know within two or three months how much vision will be restored.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

Well, the United States could be entering a new phase in the battle against the coronavirus. More and more cases are being diagnosed in this country, and those numbers may grow as testing for this dangerous new virus ramps up.

Updated at 11:50 a.m. ET

Federal health officials say they have resolved a problem that has hindered wide testing for the new coronavirus in the United States, a crucial practice for fighting the spread of the dangerous new infection.

A problem with one ingredient in test kits that the federal Centers for Disease Control and Prevention distributed to labs around the country had created a frustrating bottleneck in testing, requiring most testing to occur at the CDC in Atlanta.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

DAVID GREENE, HOST:

President Trump, at a press conference last night, chose the person who will lead the government's response to the coronavirus.

(SOUNDBITE OF PRESS CONFERENCE)

Pages